author of the a snapshot in south-east europe and particularly ... - … 2 h giamarellou.pdf ·...
TRANSCRIPT
A Snapshot
of Colistin Use
in South-East Europe and
Particularly in Greece
Helen Giamarellou 02.05.2013
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
When Greek Physicians Prescribe Colistin?
It is mainly prescribed in the ICU for VAP, bacteremia and FUO when:
There is confirmed in vitro resistance almost to all other available antibiotics including carbapenems, i.e. XDR strains of K. pneumoniae,
A. baumannii, P. aeruginosa
Empirically in critically ill patients if:
1. Extensively drug-resistant (XDR), or even pandrug-resistant (PDR)
gram-negative bacteria predominate as pathogens
2. Routinely performed surveillance cultures are already positive for XDR gram-negatives Not
to be
copie
d and
distr
ibuted
to ot
hers
withou
t the p
ermiss
ion of
the a
uthor
Colistin as Monotherapy
or in Combination?
-Europe- Greece
Santa Maria Delle Carceri church-Prato
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Greece: The Largest Cohort Study
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Analysis of Colistin Therapy for MDRa Gram-negative Infections: A Greek Retrospective Cohort Study
(Oct 2000 – Oct 2007)
No of patients 258
ICU patients 222 (86%)
APACHE II (x) 17 (2-39)
Pneumonia 155 (60%)
Bacteremia 33 (13%)
Demographic Data
Polymyxin only susceptible 135 (52.3%)
Duration of hospital or ICU stay until colistin administration (x)
18.3 versus 11.4 days
Duration of colistin administration (x) 17.9 (10-22 days)
Falagas ME, et al. IJAA 2010;35:194 a Susceptible to colistin and at least one other antibiotic
Greece
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
A Greek Study: Retrospective Analysis of Colistin Therapy
for MDR Gram-negative infections
Acinetobacter baumannii 170 (65.9%)
Pseudomonas aeruginosa 68 (26.4%)
Klebsiella pneumoniae 18 (7.0%)
Polymyxin only susceptible (XDR) 135 (52.3%)
Pathogens
Falagas ME, et al. IJAA 2010;35:194
Cure of infection 79.1%
Cure of infection in XDR pathogens 78%
Hospital survival 65.1%
Nephrotoxicity 10.4%
Results of therapy
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Colistin: Monotherapy versus Combination Therapy
83% 83%
65%
75%
61%
17% 17%
35%
25%
39%
0
10
20
30
40
50
60
70
80
90
100
COLI MONO (36) COLI+MERO (162) COLI+PIP/TAZO (17) COLI+AMP/SULB
(12)
COLI+OTHER (31)
Pe
rce
nta
ge
CURE DETERIORATION
Falagas et al, Int J Antimicrob Agents 2010
* *
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
The findings of the largest cohort study to date on IV colistin
show that colistin at least in ICU patients with A. baumannii or
P. aeruginosa infections is a valuable antibiotic with acceptable
nephrotoxicity and considerable effectiveness similar to that of
3rd gen Cephs and Carbapenems, that depends on the daily
dosage and infection site.
Falagas ME, et al. IJAA 2010; 35: 194
Conclusion:
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
• In life-threatening XDR Acinetobacter infections (VAP,
HAP, BSI, cIAI) in 210 ICU patients, 30-day mortality was
not reduced by the addition of rifampicin to colistin (43%)
• Combination treatment with Rifampicin did only increase
the rate of Acinetobacter eradication (p=0.034)
I t a l y
Durante-Mangoni E et al.Clin Infect Dis. 2013 Not
to be
copie
d and
distr
ibuted
to ot
hers
withou
t the p
ermiss
ion of
the a
uthor
The combination of colistin with rifampicin in 43 pts improved clinical, radiological and microbiological
outcomes of VAP patients infected with A. baumannii
(p=NS).
Time to microbiological clearance shorter in
combination (3.1 ± 0.5 d, p=0.029)
Mortality: 63.6% vs. 38.1% (p=0.171)
Aydemiz H, et al. Epidemiol Infect 2012
Tu r ke y
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Mortality Rates According to Treatment Regimens
0
5
10
15
20
25
30
2 Active Drugs One Active Drug No Active Drug
Mo
rtal
ity
Rat
e %
GL Daikos, et al. Antimicrob Agents Chemother 2009;53:1868
*
*
* Meropenem MIC ≤4μg/ml plus genta or colistin
G r e e c e
Prospective Observational Study of K. pneumoniae Bloodstream Infections
67 patients VIM positive
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
In vitro Synergy of Colistin and Meropenem
Colistin Synergism
Νο. of Isolates %
Susceptible 12/24 50%
Resistant 2/18 11%
Souli M, et al. Antimicrob Agents Chemother 2009; 53: 2133-35
G r e e c e
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Review of Clinical Studies with Carbapenemase Producing Klebsiella pneumoniae
34 studies were compiled after a systemic search of MEPLINE was performed
298 patients
161 infected with KPC(+) strains
140 with MBL(+) strains
244 blood stream infections
32 pneumonia
242 (81.1%) patients received appropriate therapy: at least one drug to which the infecting organism was susceptible in vitro
56 (18.9%) patients received inappropriate therapy: no drug to which the infecting organism was susceptible in vitro
Daikos GL, et al. Clin Microbiol Rev 2012; 25: 682
E u r o p e 2 0 1 1 *
* mostly
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Outcome of 294 infections* caused by carbapenemase-producing Klebsiella pneumoniae according to treatment regimen.
A B C D E F G
0
20
40
60
N=36
N=62
N=21
N=36
N=72
N=56
N=14
Treatment regimen
Failu
re (
%)
• Regimen A: combination therapy with 2 active drugs one of which was a carbapenem with MIC ≤4μg/ml; 8.3%**
• Regimen B: combination therapy with 2 active drugs not including a carbapenem; 29%
• Regimen C: monotherapy with an aminoglycoside; 24%
• Regimen D: monotherapy with a carbapenem (MIC ≤4μg/ml); 25%
• Regimen E: monotherapy with tigecycline; 35.7%
• Regimen F: monotherapy with colistin; 47.2%
• Regimen G: inappropriate therapy. 54%
*70% bacteremias, 20% VAP+HAP
A vs B p=0.02
A vs E p=0.03
A vs F p<0.0001
A vs G p<0.0001
B vs G p=0.014
C vs G p=0.04
D vs G p=0.03
** Failure rate
Daikos GL, et al. Clin Microbiol Rev 2012; 25: 682
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Carbapenemase-producing Klebsiella pneumoniae: To Treat or Not to Treat with a Carbapenem?
Carbapenem monotherapy (imipenem, meropenem, doripenem) for strains with MIC >4μg/ml should be prohibited, whereas for strains with lower MICs (≤4μg/ml) better to be avoided.
Meropenem may be a reasonable treatment option against carbapenemase producing K. pneumoniae, provided that:
i. Based on PK/PDs MIC MIC of the infecting organism is ≤4mg/L (even 8μg/ml)
ii. Carbapenem is given in combination with another active compound, i.e. colistin, tigecycline, aminoglycoside
iii. Carbapenem is given in high dose and prolonged infusions (3-4 hours)
Daikos GL, Markogiannis A. CMI 2011;17:1135
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Proposed Algorithm for the Treatment of Carbapemenase producing Enterobacteriaceae Infections
Daikos GL. Expert Review Anti-infective Therapy (December 2013)
MIC of Carbapenems
>4 mg/L ≤4 mg/L
AMG susceptible AMG resistance
CARB + AMG COL susceptible
COL resistance
CARB + COL CARB + Other AA
AMG susceptible
AMG resistance
AMG + Other AA
COL susceptible
COL resistance
COL + Other AA
Combination of Other AAs
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
• 125 patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae isolates diagnosed between 1 January 2010 and 30 June 2011
Mortality at 30-d
Monotherapy 54.3% P=0.02
Combination 34.1%
Tumbarello M, et al. CID 2012; 55: 943
I ta l y
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Tumbarello et al. CID 2012; 55: 943
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Variable P Value OR (95% CI)
Presentation with septic shock .008 7.17 (1.65-31.03)
Inadequate initial antimicrobial treatment .003 4.17 (1.61-10.76)
High APACHE III score <.001 1.04 (1.02-1.07)
Postantibiogram therapy with tigecycline + colistin + meropenem
.01 0.11 (.02-.69)
Multivariate Analysis of Risk Factors for Mortality in Patients with Bloodstream Infection Caused by Klebsiella pneumoniae
Carbapenemase-Producing K. pneumoniae
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
What Dosing Regimens
of Colistin are Typically
Used?
-Europe- Greece
Pretorium Palace-Prato
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Just to remember…
• Common Dosage Schedule in Europe: 1-3 mil units/ 8 hourly IV
Colistin (Polymyxin E) in vials containing 1 million units correspond to 80mg of CMS
1mg CMS = 12,500 units CMS
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Retrospective Analysis of Colistin Therapy of 258 MDR and XDR Gram-negative Infections:
1. Multivariate analysis: Higher daily colistin dose was
associated with increased probability of survival
(p=0.009)
Falagas ME, et al. IJAA 2010;35:194
• 38.6%
3mil iu/daily:
• 27.8%
6mil iu/daily:
• 21.7%
9mil iu/daily:
2. Mortality rate in univariate analysis:
G r e e c e 2 0 0 0 - 2 0 0 7
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
The Delay in Early Attaining Efficacious Colistin Concentrations with the
Standard Treatment Regimen of Colistin
Another Greek Explanation for the Inferior Efficacy of Colistin as Monotherapy
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Greece 2009
• Slower formation of Colistin by CMS than previously described
• Longer Colistin half-life: 14.4h
• Sub-therapeutic concentrations (0.6μg/ml), after 3MU every
8 hours, during the first day, that may lead to:
• Treatment failures
• Emergence of resistance
Plachouras D et al. AAC 2009;53:3430
Population Pharmacokinetic Analysis of Colistin after
Intravenous Administration in Critically Ill Patients with
Infections Caused by Gram-Negative Bacteria
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
The administration of a loading dose of 6 MU CMS resulted in colistin plasma concentrations above 1mg/L within 4 hours in the majority of the patients.
Mohamed et al. AAC 2012; 65: 4241 Friberg LE et al ICAAC 2010
Application of a loading dose of 6 MU CMS in critically ill patients
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Suggested Colistin Dosing for Various Patients Category Applied in Greece since the last 6-12 months
Targeting peak blood level of 2μg/ml in all patient category
9 MU Loading Dose
M a i n t e n a n c e d o s e
Normal renal function 4.5 MU every 12h Titrated in renal insufficiency (Clcr devided by 10) + 2 given in 2-3 doses S.O.S. The 1st dose should be given 24h post loading dose
In Hemodialysis 2 MU in two daily doses S.O.S. On the day of hemodialysis 30% of the daily dose should be given post hemodialysis
In continuous hemofiltration 9 MU in two or three daily doses
Garonzik SM, et al. AAC 2011;55:3284 Placouras D, et al. AAC 2009;53:3430
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
1. Adaptive resistance to the “last hope” antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by a novel two-component regulatory system ParR-ParS.
2. Does the fact of “Adaptive Resistance” indicate as appropriate single-daily dose administration of Colistin as in the aminoglycoside case?
Skiada et al. IJAA 2011; 37: 187 Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
• 28 critically ill pts with severe sepsis or septic shock suffering from
bloodstream infections (64.3%) and VAP (35.7%) caused by A. baumannii
(46.4%), K. pneumoniae (46.4%), and P. aeruginosa (7.2%)
• The CMS dosing schedule was based on a loading dose of 9 MU and a 9-
MU twice-daily fractioned maintenance dose for median duration of 12
(10-17) d, titrated on renal function
• Clinical cure was observed in 23 cases (82.1%)
• Acute kidney injury developed in 17.8% (revisible)
• Conclusion: the study showed that in severe infections, the high dose
extended interval CMS regimen has high efficacy, without significant renal
toxicity. Dalfino L, et al. CID 2012; 54: 1720
A Preliminary Study: Italy 2012
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Risk Factors of Nephrotoxicity
Co-administration of other nephrotoxic agents
(aminoglycosides, diuretics)
Mode of administration (8 vs 24 hourly)?
Daily dose?
Length of therapy?
Nephrotoxicity after colistin discontinuation is self-limited
Nephrotoxicity range: 33% - 55%
Safety of polymyxins
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Emergence
of Colistin Resistance
-Europe- Greece
Villa san Leonardo al Palco-Prato
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
G r e e c e , 2 0 0 4 - 2 0 0 5
*
* KPC-2 producers Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
41 patients with Klebsiella, Acinetobacter and
Pseudomonas infections
In the multivariable model, use of colistin >14 days
was identified as the only independent risk factor
(p=.002) for resistance development to colistin
Crit Care Med 2008; 36: 807
G r e e c e
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Colonization and Infection by Colistin Resistant Gram Negative Bacteria in a Cohort of Critically Ill Patients in Greece
Among 150 ICU patients:
52% were colonized with Colistin-R Gram-negatives:
20% with K. pneumoniae and 34% by Colistin-R Proteus spp. and Serratia spp.
25% developed infections
All cause mortality: 75%
The main risk factor was duration of colistin pretherapy (>20d)
Kontopidou F, et al. CMI 2011; 17: E9
G r e e c e 2 0 0 6
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
JAC 2011; 66: 946
In Addition to Heteroresistance in MDR Acinetobacter baumannii strains described from Australia and USA…
G r e e c e 2 0 0 9
12 heteroresistant strains with MICs: 8-64 μg/ml Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
Antibiotic MIC (μg/ml) Susceptibility
MIC50 MIC90 Min. Max. %S %I %R
Cefepime 4 >16 ≤0.5 >16 74 16 10
Ceftazidime 4 >16 ≤0.5 >16 73 9.2 18
Colistin 1 4 ≤0.12 >4 89 9.6 1.2
Gentamicin 1 >8 ≤0.25 >8 76 2.6 21
Imipenem 2 16 ≤0.03 >32 73 3 24
Levofloxacin 2 >4 ≤0.25 >4 58 7.6 34
Meropenem 0.5 8 ≤0.03 >32 81 9.6 9
Piperacillin/ tazobactam
8 >64 ≤0.5 >64 81 0 19
Haeser S. IJAA 2011; 37: 580
2 0 0 7 - 2 0 0 9 E u r o p e a n d U S A
Breakpoint: 4 μg/ml
However…
Not to
be co
pied a
nd di
stribu
ted to
othe
rs
withou
t the p
ermiss
ion of
the a
uthor
1. Mostly in ICU patients
2. Monotherapy for Acinetobacter baumannii and Pseudomonas aeruginosa
3. Combinations for carbapenemase producing Klebsiella pneumoniae
4. Loading dose!
5. Self-limited rather low nephrotoxicity
6. Resistance development in Klebsiella in connection with duration of therapy and increase in the amount of colistin use in the hospital setting Not
to be
copie
d and
distr
ibuted
to ot
hers
withou
t the p
ermiss
ion of
the a
uthor